May 15th Options Now Available For Philip Morris International (PM)

Two actionable option ideas for Philip Morris International (PM): selling-to-open the $180 put at a $5.40 bid creates an effective purchase basis of $174.60 versus the current $188.37 share price (≈4% OTM), with analytics indicating a 66% chance it expires worthless and a 3.00% return (12.04% annualized). Alternatively, buying PM at $188.37 and selling the $190 covered call at a $7.80 bid would produce a 5.01% total return if called at the May 15 expiration (or a 4.14% premium boost / 16.62% annualized if the call expires worthless); implied vols are 28% (put) and 26% (call) versus a 12-month realized volatility of 25%.

Analysis

Market structure: Short-dated option sellers and yield-seeking equity holders are the direct winners — selling the May 15 $180 put nets a 3.00% cash return (12.0% annualized) and selling the May 15 $190 covered call boosts near-term return by 4.14% (16.6% annualized). Losses accrue to buyers of upside exposure if PM gaps higher, and to naked option sellers in stress events; implied vols (26–28%) sit ~1–3pts above realized (25%), signaling modest premium available to harvested. Cross-asset effects are muted but real: PM’s EM revenue exposure makes FX moves (USD up 5%+ over a month) a material P&L driver; credit spreads likely stable but would widen on regulatory shocks, lifting options vol sharply.

Risk assessment: Tail risks include abrupt regulatory action (US/EU nicotine caps, menthol bans, or large excise hikes) that could drive 20–40% multi-week drawdowns, and EM currency devaluations >10% compressing earnings—both low-probability but high-impact within 3–12 months. Immediate (days) risk is gamma/theta around May 15 expiries; short-term (weeks) risk includes earnings or FDA commentary; long-term (quarters/years) remains secular cigarette volume decline offset by NGP growth and buybacks. Hidden dependencies: corporate hedges, tax timing, and litigation reserves — poor disclosure can suddenly widen realized volatility.

Trade implications: Tactical trade: cash-secured sale of May 15 $180 puts or buy-and-write with $190 calls to capture ~3–4% to expiry (size 1–3% portfolio), rolling only if stock moves >5% adverse or IV>35%. Defensive alternative: defined-risk put spread (sell $180/buy $170 May) to limit tail loss to ~$9. Quant pair: long PM / short MO (equal-dollar) for 3–12 months to express international pricing power and lower U.S. regulatory overhang; stop-loss on pair divergence >10%.

Contrarian angles: Consensus underweights FX and buyback optionality — a 5–10% rebound in EM currencies or an aggressive buyback could drive >15% upside within 6–12 months, making short-dated income trades a low-cost entry. Conversely, selling naked puts is underpriced for regulatory cat risk; consider spreads if you discount that risk. Historical precedent: tobacco stocks have snapped back after regulatory headlines (2014–2016), but outcomes vary; avoid concentrated assignment ahead of any major FDA decision (next 30–90 days).

Key Decisions for Investors

• Sell-to-open cash-secured PM May 15 $180 puts size 1–2% of portfolio (target cost basis $174.60 if assigned); close or roll if PM falls below $170 or implied vol rises above 35% (time horizon: 0–1 month).
• If bullish, establish a buy-and-write: buy PM up to 2% portfolio and sell May 15 $190 calls to collect ~4.14% to expiry; buy back/roll if PM >$190 or within 3 trading days of expiry (time horizon: up to 1 month).
• If concerned about regulatory tail risk, enter a defined-risk put spread: sell May 15 $180 / buy May 15 $170 puts (max loss ~$9 less net premium); size 0.5–1% portfolio to limit downside exposure (horizon: until May expiry).
• Implement a relative-strength pair: long PM / short MO equal-dollar 1–2% portfolio to express international NGP exposure; hold 3–12 months and trim if relative performance diverges >10% or if FDA issues binding nicotine/menthol rule within 60 days.
• Delay increasing PM exposure above 3% until after the next major regulatory/earnings catalyst (expect FDA commentary or quarterly results within 30–60 days); treat any sharp IV spike (>5 pts) as an opportunity to sell volatility via spreads rather than naked positions.